Winton Matthew 4

What Happened
Matthew Winton, CervoMed’s Chief Commercial and Business Officer, received a grant (derivative award) of 30,000 shares on 2026-02-11. The award was reported at $0.00 per share (no cash paid), so the reported acquisition value is $0. This is an equity award rather than a purchase or sale.

Key Details

• Transaction date: 2026-02-11; Form 4 filed: 2026-02-13 (appears timely).
• Transaction type/code: Grant/Award (A), 30,000 shares, $0.00 per share (derivative).
• Vesting: The shares vest in 36 equal (or near-equal) monthly installments on the last calendar day of each month beginning February 28, 2026 (per footnote F1).
• Shares owned after transaction: Not specified in the provided filing.
• No indication of a 10b5-1 plan, tax-withholding sale, or immediate sale of underlying shares in this filing.

Context
This is a standard time-based equity award (likely restricted stock or RSUs) intended to incentivize and retain the executive; vesting over three years means the recipient must remain employed to receive the full grant. Because the grant was recorded at $0, it does not reflect an immediate cash investment or sale by the insider and should be interpreted as compensation rather than a direct bullish or bearish market signal.